GMAB Genmab Forward P/S Multiple

genmab.com (GMAB) - corporate logo

Competent management at Genmab A/S ensures payment transparency and scientific success in antibody development. The projected P/S multiple visualizes market revenue expectations, while 5.30 determines the latest valuation metric. Business efficiency relies on external clinical trial partners and the high margins of proprietary drugs, guaranteeing the global scaling of sales.

GMAB (genmab.com) Price to Expected Revenue Ratio history from 07/04/2022 to 11/13/2026

Genmab Corp - analytical breakdowns and key metrics (GMAB)

- current price and projected stock value:
Stock Price Genmab|GMAB - Analyst Target Range
- market capitalization data:
Market Capitalization Genmab Corp|GMAB - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Genmab|GMAB - Total Net Assets|Market Capitalization to Book Value Ratio genmab.com|GMAB - Company Assets
- debt and liquidity data:
Total Debt to Capital Genmab A/S|GMAB - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Genmab A/S|GMAB - Aggregate Debt Obligations|Debt to Book Value Genmab Corp|GMAB - Amount of Long-Term Liabilities|Company Short-Term Debts Genmab|Quick Ratio genmab.com
- net income and valuation multiples indicators:
GMAB - Company Net Income|Expected Profit Genmab A/S|GMAB - Company Value to Net Income|Forward P/E Multiple Genmab US|GMAB - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genmab Corp|GMAB - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Genmab|GMAB - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth genmab.com|GMAB - Net earnings per share change in current year|Earnings growth forecast for next year Genmab A/S
- issuer revenue and sales details:
GMAB - Company Total Revenue|Company Projected Revenue Genmab|GMAB - Market Cap to Revenue Ratio|Price-to-Projected Revenue Ratio Genmab Corp
Summary company analysis:Genmab (GMAB)
Product sample of genmab.com

Forward P/S determines the market value of an asset relative to expected revenue, allowing for an assessment of the premium paid for future cash flow. By analyzing the forward P/S indicator, an investor can observe the dynamics of market expectations and the risk of multiple compression. For Genmab A/S (GMAB), this metric reflects the monetization potential of breakthrough oncology developments and the value of a robust R&D pipeline of bispecific antibodies.

Competing companies

Forward P/S Multiple EXEL (Exelixis)|Projected Price to Revenue Nuvalent Inc|Kymera Therapeutics Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio IDEAYA Corp|ELVN (Enliven Therapeutics) - Forward Price-to-Revenue Multiple|ORIC: Price to Expected Revenue Ratio|RLAY (Relay Therapeutics, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Nurix Therapeutics Inc NRIX|Forward P/S Multiple TYRA|Verastem Corp - Market Cap to Projected Revenue|Monte Rosa Therapeutics - Forward Price-to-Revenue Multiple|Forward Price to Sales CGEM|IMRX: Forward Price-to-Revenue Multiple|C4 Therapeutics Inc - Price to Expected Revenue Ratio|BDTX: Forward P/S Multiple|Repare Therapeutics Inc - Forward Price to Sales|PMVP (PMV Pharmaceuticals) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Karyopharm KPTI|Price-to-Projected Revenue Ratio Propanc Biopharma Inc (PPCB)|BGMS (Bio Green Med Solution Inc.) - Forward Price to Sales|Forward P/S Multiple AADI (Aadi Bioscience, Inc.)|Forward P/S Multiple Aileron Therapeutics Inc ALRN|BPMC - Price-to-Projected Revenue Ratio|Future Price to Revenue GLYC|SWTX (SpringWorks Therapeutics, Inc.) - Forward Price-to-Revenue Multiple